Why it matters: The Detroit cancer center’s registration amendment signals intensified advocacy as Medicare payment rules face major changes. Karmanos has maintained the same lobbying firm for nearly two decades while pursuing coveted PPS-exempt status that could boost reimbursements by 42%.
By the numbers: Franklin Partnership has represented Karmanos since 2006, filing 73 disclosures totaling $1.97 million. Lead lobbyist John M. Guzik brings healthcare expertise from 65 Karmanos filings plus experience with autism care funding and hospital appropriations. The institute previously used multiple firms but now focuses exclusively on Medicare/Medicaid through Franklin Partnership.
Broader context: The FY 2026 Medicare payment rule takes effect October 1, implementing significant changes to hospital reimbursement formulas. CMS discontinued the low-wage index hospital policy that benefited Detroit-area providers. The Trump administration’s deregulation push creates scrutiny for special payment arrangements like cancer hospital exemptions.
The agenda: Karmanos is lobbying on Medicare/Medicaid reimbursement issues. The institute has been working toward PPS-exempt cancer hospital status, which would provide substantial payment increases. Current policy changes include new quality reporting requirements and bundled payment models for surgical procedures.
Competitive landscape: Karmanos competes with 11 existing PPS-exempt cancer hospitals that already enjoy higher Medicare payments. A 2015 GAO report criticized these exemptions, recommending Congress eliminate the $500 million annual cost difference. Academic debates continue defending the exemption against growing political pressure.
Between the lines: The October timing aligns with critical policy deadlines as new Medicare rules take effect. Karmanos faces threats from discontinued wage policies and bundled payment models that may not account for cancer care complexity. The institute needs favorable interpretation of new quality reporting requirements for PPS-exempt hospitals.
The bottom line: Karmanos maintains steady advocacy through proven relationships as Medicare policies shift. The institute balances protecting current reimbursement levels while pursuing more favorable payment status amid mounting scrutiny of cancer hospital exemptions.
Spot something wrong? Report an issue with this article